These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

53 related articles for article (PubMed ID: 762000)

  • 21. In vitro activity of five oral cephalosporins against anaerobic pathogenic bacteria.
    Shadomy S; Mayhall CG; Apollo E
    J Infect Dis; 1977 Nov; 136(5):697-700. PubMed ID: 915342
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Activity of beta-lactamase produced by Bacteroides fragilis against newly introduced cephalosporins.
    Sato K; Inoue M; Mitsuhashi S
    Antimicrob Agents Chemother; 1980 Apr; 17(4):736-7. PubMed ID: 6967295
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Comparison of the activity of imipenem and beta-lactams combined with sulbactam and clavulanic acid in beta-lactamase-producing strains of Bacteroides fragilis.
    Martín MA; Castillo AM; Liébana J; Marín A; Alados JC; Piédrola G
    J Hyg Epidemiol Microbiol Immunol; 1991; 35(2):189-97. PubMed ID: 1940333
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Comparative bacteriostatic activity of ticarcillin, alone and combined with clavulanic acid, 5 cephalosporins and metronidazole against 100 strains of Bacteroides fragilis].
    de Barbeyrac B; Quentin C; Bebear C
    Pathol Biol (Paris); 1984 May; 32(5):433-5. PubMed ID: 6739151
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Comparative in vivo efficiency of cefamandole and cefoxitin against Bacteroides fragilis.
    Bergeron MG; Gauvreau L; Nguyen BM
    Scand J Infect Dis Suppl; 1980; suppl 25():60-5. PubMed ID: 6937954
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Comparative in vitro activity of 4 cephalosporins on Bacteroides fragilis].
    Castillo AM; Fernández-Crehuet M; Ocete MD; Liébana JJ; Cueto A; Maroto MC; Piédrola MG
    Med Clin (Barc); 1986 Apr; 86(15):624-6. PubMed ID: 3724274
    [No Abstract]   [Full Text] [Related]  

  • 27. [Susceptibility of anaerobic bacteria to cefoxitin (author's transl)].
    Freydière AM; Gille Y; Marcel JP; Vincent P
    Sem Hop; 1980 Nov 18-25; 56(43-44):1793-5. PubMed ID: 6256880
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Activity of HR 756 against Haemophilus influenzae, Bacteroides fragilis and Gram-negative rods.
    Drasar FA; Farrell W; Howard AJ; Hince C; Leung T; Williams JD
    J Antimicrob Chemother; 1978 Sep; 4(5):445-50. PubMed ID: 308506
    [No Abstract]   [Full Text] [Related]  

  • 29. Antibiotic susceptibility of anaerobic bacteria with special reference to Bacteroides fragilis.
    Dornbusch K; Nord CE; Olsson-Liljeqvist B
    Scand J Infect Dis Suppl; 1979; (19):17-25. PubMed ID: 37593
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The comparative activity of cefsulodin against anaerobic bacteria of clinical interest: synergy with cefoxitin.
    Watt B; Brown FV
    J Antimicrob Chemother; 1981 Mar; 7(3):269-78. PubMed ID: 6974166
    [No Abstract]   [Full Text] [Related]  

  • 31. beta-lactamases in bacteroides.
    Nord CE; Olsson B; Dornbusch K
    Scand J Infect Dis Suppl; 1978; (13):27-32. PubMed ID: 28561
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [In vitro activity of cefotaxime on anaerobes (author's transl)].
    Soussy CJ; Thibault M; Duval J
    Nouv Presse Med; 1981 Feb; 10(8):556-8. PubMed ID: 6259592
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The activity of five cephalosporins against Bacteroides fragilis.
    Ryan RW; Kwasnik I; Tilton RC
    Ann Clin Lab Sci; 1982; 12(1):32-4. PubMed ID: 6279014
    [No Abstract]   [Full Text] [Related]  

  • 34. Increase in the activity of third-generation cephalosporins in combination with clavulanic acid and Sulbactam against Bacteroides fragilis.
    Martín MA; Castillo AM; Liebana J; Mesa P; Piedrola G; Gutierrez J
    Med Lab Sci; 1990 Jul; 47(3):163-7. PubMed ID: 2402195
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Bacteroides fragilis septicemia during cefamandole therapy.
    Righter J
    Can Med Assoc J; 1981 Sep; 125(5):422, 424. PubMed ID: 7284925
    [No Abstract]   [Full Text] [Related]  

  • 36. The in-vitro activity of three long-acting cephalosporins against Bacteroides fragilis, Peptostreptococcus species and Clostridium perfringens.
    Watt B; Naden MG
    J Chemother; 1989 Jul; 1(4 Suppl):106-7. PubMed ID: 16312326
    [No Abstract]   [Full Text] [Related]  

  • 37. In vitro bactericidal activities and morphologic changes in Escherichia coli and Bacteroides fragilis by cephalosporins.
    Mikamo H; Kawazoe K; Sato Y; Hayasaki Y; Satoh M; Kai J; Tamaya T
    Chemotherapy; 1998; 44(3):157-63. PubMed ID: 9612605
    [TBL] [Abstract][Full Text] [Related]  

  • 38. In vitro activity of cefotetan, a new cephamycin derivative, compared with that of other beta-lactam compounds.
    Wise R; Andrews JM; Hancox J
    Antimicrob Agents Chemother; 1982 Mar; 21(3):486-91. PubMed ID: 6954875
    [TBL] [Abstract][Full Text] [Related]  

  • 39. In vitro activity of CGP 31523A, a broad-spectrum cephalosporin, in comparison with those of other agents.
    Wise R; Cross C; Andrews JM
    Antimicrob Agents Chemother; 1984 Dec; 26(6):876-80. PubMed ID: 6524904
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Moxalactam (6059-S), a novel 1-oxa-beta-lactam with an expanded antibacterial spectrum: laboratory evaluation.
    Yoshida T; Matsuura S; Mayama M; Kameda Y; Kuwahara S
    Antimicrob Agents Chemother; 1980 Mar; 17(3):302-12. PubMed ID: 6448572
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 3.